Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by equities research analysts at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell from a “buy” rating to a “neutral” rating in a research report issued on Thursday, AnalystRatings.net reports. They presently have a $14.00 price target on the biopharmaceutical company’s stock.
Several other analysts have also recently issued reports on the company. Smith Barney Citigroup raised Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Thursday, October 29th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 1st. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Thursday, December 17th. Finally, UBS Group raised shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Thursday, October 29th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $15.50.
Vanda Pharmaceuticals stock opened at $14.00 on Thursday. Vanda Pharmaceuticals has a 52-week low of $7.12 and a 52-week high of $15.70. The stock has a market capitalization of $765.69 million, a price-to-earnings ratio of 6.70 and a beta of 0.48. The stock’s 50 day moving average price is $13.26 and its two-hundred day moving average price is $11.51.
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 125,252 shares of the business’s stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $13.04, for a total transaction of $1,633,286.08. 5.90% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisor Group Holdings Inc. boosted its holdings in Vanda Pharmaceuticals by 43.0% during the 2nd quarter. Advisor Group Holdings Inc. now owns 3,732 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,122 shares during the period. Meeder Asset Management Inc. raised its position in Vanda Pharmaceuticals by 79.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 5,661 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 2,502 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at $73,000. Diversified Trust Co bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $99,000. Finally, Pacer Advisors Inc. lifted its position in shares of Vanda Pharmaceuticals by 109.0% in the 3rd quarter. Pacer Advisors Inc. now owns 10,817 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 5,641 shares during the period.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia.
Recommended Story: Monthly Dividend Stocks
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.